Medimetriks Pharmaceuticals, Inc.
http://www.medimetriks.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medimetriks Pharmaceuticals, Inc.
Otsuka Dermatitis Candidate Looks Good At Phase III
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead
Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice